)

Mohan Srinivasan
With over 25 years of experience in biologics innovation, discovery, and preclinical development, Mohan Srinivasan is a recognized leader in the development of monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and multispecific biologics. He is a listed co-inventor of multiple therapeutic antibodies across oncology and immuno-oncology—including foundational contributions to nivolumab and relatlimab—as well as several biologics platforms.
Mohan has created foundational intellectual property and advanced antibody product pipelines, and he is the co-founder of an award-winning therapeutic antibody start-up. Known for his scientific vision and operational leadership, he also actively mentors biotech entrepreneurs and biologics startups. His mission is to develop innovative biological medicines that improve outcomes for patients with intractable diseases.